Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of capecitabine + oxaliplatin + irinotecan in metastatic colorectal cancer
2005-005846-37Phase 2Active
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- Jan 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine, oxaliplatin and irinotecan in colorectal cancer (CRC), sponsored by G.O.N.O. - Gruppo Oncologico del Nord Ovest. Primary endpoint: Maximum tolerated dose. Started Jan 2006; status: active.
02
Drugs
capecitabineoxaliplatinirinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2005-005846-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005846-37.